Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 1;22(8):830-831.
doi: 10.36849/jdd.7241.

Juvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab

Case Reports

Juvenile Pemphigus Foliaceus in a Patient With Psoriasis Receiving Narrow-Band Ultraviolet-B: Successful Treatment With Rituximab

Jenna Yousif et al. J Drugs Dermatol. .

Abstract

Pemphigus foliaceus is an autoimmune blistering disease of the skin that is not frequently associated with mucous membrane involvement. It is characterized by immunoglobulin G (IgG) antibodies against desmoglein-1, a component of epidermal intercellular adhesion, in the granular layer of the epidermis. Pemphigus foliaceus consists of scattered, arcuate, crusted erythematous lesions often in a seborrheic distribution that may progress to diffuse skin involvement and exfoliative erythroderma. Several cases in the literature discuss pemphigus foliaceus arising in patients with pre-existing psoriatic disease following treatment with narrow-band ultraviolet-B (NB-UVB) therapy. Although this is a rare occurrence and the exact mechanism of this phenomenon remains unclear, providers should be aware of this association to better improve management and care. We present a case of a 16-year-old-male who developed pemphigus foliaceus following NB-UVB treatment for psoriasis.Yousif J, Gottlieb AB, Al-Dehneem R. Juvenile pemphigus foliaceus in a patient with psoriasis receiving narrow-band ultraviolet-b: successful treatment with rituximab. J Drugs Dermatol. 2023;22(8):830-831. doi:10.36849/JDD.7241.

PubMed Disclaimer

Similar articles

Cited by

Publication types

LinkOut - more resources